Kashima Y, Kaneko K, Reteng P, Yoshitake N, Runtuwene R.L, Nagasawa S, Onishi M, Seki M, Suzuki A, Sugano S, Sakata-Y M, Imai Y,
Nakayama-H K, kawana-T A, Mizutani T, Suzuki Y.
Intensive single-cell analysis reveals immune-cell diversity among healthy individuals.
Life Science Alliance, 2022;:1-16.
Yamada A, Hayashi N, Kumamaru H, Nagahashi M, Usune S, Asaga S, Iijima K, Kadoya T, Kojima Y, Kubo M, Miyashita M, Miyata H, Ogo E, Tamura K, Tanakura K, Tada K, Niikura N, Yoshida M, Ohno S, Ishikawa T, Narui K, Endo I, Imoto S, Jinno H.
Prognostic impact of postoperative radiotherapy in patients with breast cancer and with pT1-2 and 1-3 lymph node metastases: A retrospective cohort study based on the Japanese Breast Cancer Registry.
European journal of cancer, 2022;172:31-40.
Shimomura A, Nagahashi M, Kumamaru H, Aogi K, Asaga S, Hayashi N, Iijima K, Kadoya T, Kojima Y, Kubo M, Miyashita M, Miyata H, Niikura N, Ogo E, Kenji T, Tanakura K, Yoshida M, Yamamoto Y, Imoto S, Jinno H.
Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan.
Breast Cancer, 2022;:https://doi.org/10.1007/s12282-022-01378-6.
Miyake S, Oka M, Kanai A, Kawai Y, Nagasawa S, Shiraishi Y, Tokunaga K, Kohno T, Seki M, Suzuki Y, Suzuki A.
Phasing analysis of lung cancer genomes using a long read sequencer.
Nature Communications, 2022;13(1):e3464.
Udagawa C, Kuah S, Shimoi T, Ken Kato, Yoshida T, Nakano H M, Shimo A, Kojima Y, Yoshie R, Tsugawa K, Mushiroda T, Tan E Y, Zembutsu H.
Replication study for the association of five SNPs identified by GWAS and Trastuzumab-induced cardiotoxicity in Japanese and Singaporean cohorts.
Biological & Pharmaceutical Bulletin, 2022;45(8):1198-1202.
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Cancer Science, 2022;113:3169-3179.
Muto K, Tsuchiya I, Kim S H, Nagasawa S, Takishita M, Tsugawa K, Saito H, Komazaki Y, Torii T, Fujii T, Suzuki Y, Suzuki A, Seki M. Semibulk RNA-seq analysis as a convenient method for measuring gene expression statuses in a local cellular environment.
Scientific Reports, 2022;12(1):15309.
Aihara T, Kumamaru H, Ishitobi M, Miyashita M, MIyata H, Tamura K, Yoshida M, Ogo E, Nagahashi M, Asaga S, Kojima Y, Kadoya T, Aogi K, Niikura N, Iijima K, Hayashi N, Kubo M, Yamamoto Y, Takeuchi Y, Imoto S, Jinno H.
Prognosis and effectiveness of chemotherapy for medullary breast carcinoma.
Breast cancer research and treatment, 2022;:https://doi.org/10.1007/s10549-022-06749-3.
Udagawa C, Nakano H M, Yoshida T, Ohe Y, Kato K, Mushiroda T, Zembutsu H.
Association between genetic variants and the risk of nivolumab-induced immune-related adverse events.
Pharmacogenomics, 2022;23(16):887-901.
Yamaguchi A, Ishitobi M, Nagura N, Shimo A, Seki H, Ogiya A, Sakurai T, Seto Y, Oshiro C, Sasada S, Kato M, Kawate T, Kondo N, Narui K, Nakagawa T, Nogi H, Yamauchi C, Tsugawa K, Kajiura Y, Shien T.
Classification of local recurrence after Nipple-Sparing mastectomy based on location: The features of Nipple-Areolar recurrence differ from those of other local recurrences.
Annals of surgical oncology : the official journal of the Society of Surgical Oncology, 2022;3:1678-1686.
Mori T, Okamoto Y, Anfeng M, Ide Y, Yoshimura A, Senda N, Kawata I Y, Kawashima M, Kitao H, Tokunaga E, Miyoshi Y, Ohsumi S, Tsugawa K, Ohta T, Katagiri T, Ohtsuru S, Koike K, Ogawa S, Toi M, Iwata H, Nakamura S, Matsuo K, Takata M.
Lack of impact of the ALDH2 rs671 variant on breast cancer development in Japanese BRCA1/2-mutation carriers.
Cancer Medicine, 2022;12(6):6594-6602.
Sawaki M, Taira N, Uemura Y, Saito T, Baba S, Kobayashi K, Kawashima H, Tsuneizumi M, Sagawa N, Bando H, Takahashi M, Yamaguchi M, Takashima T, Nakayama T, Kashiwaba M, Mizuno T, Yamamoto Y, Iwata H, Toyama T, Tsugawa K, Kawahara T, Mukai H.
RESPECT study group. Adjuvant trastuzumab without chemotherapy for treating early HER2-positive breast cancer in older patients: A propensity score-adjusted analysis of a prospective cohort study.
The Breast, 2022;66:245-254.
Hattori M, Masuda N, Takano T, Tsugawa K, Inoue K, Matsumoto K, Ishikawa T, Itoh M, Yasojima H, Tanabe Y, Yamamoto K, Suzuki M, Pan W, Cortes J, Hiroji I.
Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355.
Cancer Medicine, 2023;:1-14.
Tsugawa K, Masuda N, Takano T, Inoue K, Matsumoto K, Ishikawa T, Ito M, Hattori M, Yasojima H, Tanabe Y, Yamamoto K, Suzuki M, Pan W, Karantza V, Cortes J, Iwata H
KEYNOTE-355 Japan subset: Pembrolizumab+Chemotherapy vs Placebo+Chemotherapy for TNBC.
第30回日本乳癌学会学術総会, 2022.
Mukai H, Takahashi M, Ohno S, Inoue K, Tsugawa K, Watanabe J, Ito M, Watanabe K, Mukohara T, Yamamoto K, Adachi N, Zhao J, Pan W, Schmid P, Iwata H.
Pembrolizumab/Placebo+Chemo in early Triple-Negative breast cancer : KEYNOTE-522 Japan subgroup.
第30回日本乳癌学会学術総会, 2022.
Tsugawa K, Motoyoshi A
The management of HBOC in Japan.
28th Chezh-Japan Surgical Symposium YOKOHAMA2022, 2022.
Nishikawa T, Kanemaki Y, Kojima Y, Yokota K, Sone M, Fukuda M, Tsugawa K.
Is non-contrast MRI useful in the Localization of parathyroid tumors?.
29th Czech-Japan Surgical Symposium YOKOHAMA2022, 2022.